How to buy Luminex Corporation stock

Luminex Corporation is a medical instruments & supplies business based in the US. Luminex Corporation shares (LMNX) are listed on the NASDAQ and all prices are listed in US Dollars. Luminex Corporation employs 1,325 staff and has a trailing 12-month revenue of around 0.00.

Luminex Corporation stock price (NASDAQ: LMNX)

Use our graph to track the performance of LMNX stocks over time.

Luminex Corporation shares at a glance

• Key figures

Information last updated 2021-09-12.

Latest market close	$36.89
52-week range	$24.68 - $37.18
50-day moving average more info button	$36.84
200-day moving average more info button	$33.44
Wall St. target price	$37.00
PE ratio more info button	73.8323
Dividend yield more info button	$0.38 (1.03%)
Earnings per share (TTM) more info button	$0.50

Buy Luminex Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Luminex Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Luminex Corporation price performance over time

Historical closes compared with the close of $36.89 from 2021-05-28

1 week (2022-01-15)	N/A
1 month (2021-12-22)	N/A
3 months (2021-10-22)	N/A
6 months (2021-07-22)	N/A

1 year (2021-01-26)	31.89%
2 years (2020-01-24)	63.88%
3 years (2019-01-25)	34.78%
5 years (2017-01-26)	86.60%

Is Luminex Corporation stock undervalued or overvalued?

Valuing Luminex Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Luminex Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Luminex Corporation's P/E ratio

Luminex Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 74x. In other words, Luminex Corporation shares trade at around 74x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Luminex Corporation's PEG ratio

Luminex Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.7. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Luminex Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Luminex Corporation's EBITDA

Luminex Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $85.6 million.

The EBITDA is a measure of a Luminex Corporation's overall financial performance and is widely used to measure a its profitability.

Luminex Corporation financials

Revenue TTM	$437.7 million
Operating margin TTM	12.49%
Gross profit TTM	$247.9 million
Return on assets TTM	5.06%
Return on equity TTM	4.97%
Profit margin	5.39%
Book value	$10.55
Market capitalisation more info button	$1.8 billion

TTM: trailing 12 months

Luminex Corporation share dividends

Dividend payout ratio: 1.63% of net profits

Recently Luminex Corporation has paid out, on average, around 1.63% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.08% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Luminex Corporation shareholders could enjoy a 1.08% return on their shares, in the form of dividend payments. In Luminex Corporation's case, that would currently equate to about $0.38 per share.

While Luminex Corporation's payout ratio might seem low, this can signify that Luminex Corporation is investing more in its future growth.

Luminex Corporation's most recent dividend payout was on 7 July 2021. The latest dividend was paid out to all shareholders who bought their shares by 15 June 2021 (the "ex-dividend date").

Luminex Corporation share price volatility

Over the last 12 months, Luminex Corporation's shares have ranged in value from as little as $24.6764 up to $37.179. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Luminex Corporation's is 0.5734. This would suggest that Luminex Corporation's shares are less volatile than average (for this exchange).

Luminex Corporation overview

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. Luminex Corporation was founded in 1995 and is based in Austin, Texas. .

Frequently asked questions

What percentage of Luminex Corporation is owned by insiders or institutions?
Currently 4.354% of Luminex Corporation shares are held by insiders and 92.552% by institutions. How many people work for Luminex Corporation?
Latest data suggests 1,325 work at Luminex Corporation. When does the fiscal year end for Luminex Corporation?
Luminex Corporation's fiscal year ends in December. Where is Luminex Corporation based?
Luminex Corporation's address is: 12212 Technology Boulevard, Austin, TX, United States, 78727 What is Luminex Corporation's ISIN number?
Luminex Corporation's international securities identification number is: US55027E1029 What is Luminex Corporation's CUSIP number?
Luminex Corporation's Committee on Uniform Securities Identification Procedures number is: 55027E102